Ami S. Lakdawala

TL;DR: This work highlights a common mechanism unveiling RHIM-driven apoptosis by therapeutic or genetic perturbation of RIP3, which holds both necroptosis and apoptosis in balance through a Ripoptosome-like platform.

TL;DR: This work elucidate the conformation of RIP1 bound to this benzoxazepinone inhibitor driving its high kinase selectivity and design specific mutations in murine RIP1 to restore potency to levels similar to primate RIP1.

TL;DR: A new methodology that successfully predicts the druggability and maximal binding affinity for a series of challenging targets, including those that function through allosteric mechanisms, and provides insights into novel druggable sites and the target’s structural changes that would accommodate, if not promote and stabilize, drug binding.

TL;DR: Experimental and theoretical evidence that Taxol adopts a T-shaped conformation when it is bound to tubulin is presented.

TL;DR: The discovery and pharmacological characterization of GSK583, a next-generation RIP2 inhibitor possessing exquisite selectivity and potency is presented, further clarifying the understanding of the role of RIP2 in NOD1 and NOD2 mediated disease pathogenesis.